Antithrombin substitution therapy

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 3, 1998, Pages

  Schinzel, H ^a   Weilemann, L S ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antithrombin; Antithrombin deficiency; Antithrombin substitution; Consensus guidelines; Sepsis

Indexed keywords

ANTITHROMBIN;

ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; CONFERENCE PAPER; DRUG EFFECT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; TREATMENT INDICATION;

ANTITHROMBINS; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; SEPSIS; THROMBOEMBOLISM;

EID: 0032464493     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkor NP, Boulyjenkov V et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-662.
2. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkor NP, Boulyjenkov V et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-834.
3. Pabinger I, Brucker S, Kyrie PA, Schneider B, Korninger HC, Niessner H et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibrinol 1992; 3: 547-553.
4. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 1993; 69: 98-102.
5. Dickneite G. The influence of antithrombin III (AT III) on experimental sepsis. Shock 1997; 7 (suppl): 648A.
6. Redens TB, Emerson TE Jr. Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 1989; 28: 49-58.
7. Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989; 87 (suppl 3B): 27S-33S.
8. Okajima K, Uchiba M, Murakami K. Antithrombin replacement in disseminated intravascular coagulation and multiple organ failure. In: Vincent JL (editor): Yearbook of intensive care and emergency medicine. Heidelberg: Springer-Verlag; 1995. pp. 457-464.
9. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
10. th European Congress on Intensive Care Medicine. Bologna, Italy: Monduzzi Editore S.p.A.; 1996. p. 385.
11. Inthorn D, Hoffmann JN, Hard WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997; 8: 328-334.
12. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995; 32 (4 suppl 2): 19-32.
13. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A et al. Septic shock, multiple organ failure and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
14. Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM. Antithrombin levels related to infections and outcome. J Trauma 1996; 3: 384-387.
15. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-1542.
16. Blajchman MA, Austin RC, Fernandez-Rachubinski F, Sheffield WP. Molecular basis of inherited human antithrombin deficiency. Blood 1992; 80: 2159-2171.
17. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Haemost 1994; 20: 353-372.
18. Lane DA, Caso R. Antithrombin: structure, genomic organisation, function and inherited deficiency. Bailleres Clin Haematol 1989; 2: 961-968.
19. Schreuder HA, de Boer B, Dijkema R, Mulder JS, Theunissen HJ, Grootenhuis PD et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol 1994; 1: 48-54.
20. Blauhut B, Necek S, Kramar H, Vinazzer H, Bergmann H. Activity of antithrombin III and effect of heparin on coagulation in shock. Thromb Res 1980; 19: 775-782.
21. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989; 163: 1404-1411.
22. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
23. Lane DA, Olds RR, Thein S-L. Antithrombin and its deficiency states. Blood Coag Fibrinol 1992; 3: 315-341.
24. Chowdhury V, Lane DA, Mille B, Auberger K, Gandenberger-Bachem S, Pabinger I et al. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
25. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-761.
26. De Stefano V, Leone G, Matrangelo S, Tripodi A, Rodeghiero F, Castaman G et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
27. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophiha: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-3544.
28. Wells PS, Blajchman MA, Henderson P, Wells MJ, Demers C, Bourque R et al. Prevalence of antithrombin III deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45: 321-324.
29. Vinazzer H. Indikationen zur Antithrombinbestimmung. In: Weilemann LS, Schinzel H (editors): Antithrombin - Diagnostik und Therapie. Heidelberg/Berlin/New York: Springer-Verlag; 1997. pp. 17-19.
30. De Stefano V, Leone G, De Carolis S, Ferelli R, Di Donfrancesco A, Moneta E et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988; 59: 193-196.
31. Hiller E, Salat C, Kempter B. Antithrombin III deficiency and pregnancy - successful management with LMW-heparin. Ann Hematol 1992; 64 (suppl): A111.
32. Joist JH. Hemostatic abnormalities in liver disease. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW (editors): Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: JB Lippincott Company; 1994. p. 906.
33. Schipper HG, ten Cate JW. Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol 1982; 52: 25-33.
34. Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967; 19: 190-195.
35. Heimburger N. First International Symposium on Tissue Factors in the Hemostasis of the Coagulation-Fibrinolysis System. Florence, 1967. p. 353.
36. Miller-Andersson M, Borg H, Andersson L-O. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452.
37. Eriksson B. A double virus-inactivated and highly purified antithrombin III concentrate [abstract 651]. Shock 1997; 7 (suppl): 162.
38. Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent-detergent-treated blood product. Blood Coagul Fibrinolysis 1994; 5 (suppl 3): 21-28.
39. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 1989; 15: 347-352.
40. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985; 39: 81-89.
41. van Beek JE, von der Mohlen MA, ten Cate JW, Brandjes DP, Butter HR. Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study. Neth J Med 1994; 45: 206-210.
42. Vinazzer H. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thrombosis/Hemostasis 1995; 1: 62-65.
43. Gabriel DA. The use of antithrombin III in the treatment of disseminated intravascular coagulation. Semin Hematol 1994; 31: 60-67.
44. Olson ST, Bjork I. Role of protein conformational changes, surface approximation and protein cofactors in heparin-accelerated antithrombin-proteinase reactions. Adv Exp Med Biol 1992; 313: 155-165.
45. Marciniak E, Gockerman J. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; ii: 581-584.